2024 ACC/AHA Guidelines on Hypertrophic Cardiomyopathy

https://is1-ssl.mzstatic.com/image/thumb/Podcasts122/v4/82/43/b7/8243b73b-2d11-1311-21be-68683a295068/mza_12804423687283069731.jpg/600x600bb.jpg

'Why we do What we do in Cardiology'

Bishnu Subedi

35 episodes

4 days ago

I am Dr. Bishnu Subedi. I am a cardiologist in the United States. In the era of evidence-based medicine, our practice is usually guided by a scientific study, expert society statements, or clinical guidelines. In this podcast series, I intend to highlight some of these practice-changing articles in the field of cardiology from past and present.

Medicine

Health & Fitness

RSS

All content for 'Why we do What we do in Cardiology' is the property of Bishnu Subedi and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/5443800/5443800-1710051687903-3d02caa2ebc39.jpg

2024 ACC/AHA Guidelines on Hypertrophic Cardiomyopathy

'Why we do What we do in Cardiology'

9 minutes 23 seconds

1 year ago

2024 ACC/AHA Guidelines on Hypertrophic Cardiomyopathy

2024 HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

Mavacamten: Class 1 recommendation for symptomatic obstructive HCM.
Exercise: Now allows for "vigorous" activity; competitive level still limited.
Pediatric Section: Separate guidelines with new risk-prediction tools.
Atrial Fibrillation: Enhanced monitoring is recommended.
Future Research: Needed on nonobstructive HCM and cardiac myosin inhibitors' long-term effects.